Chemoresistance in ovarian cancer linked to expression of microRNAs

References

• Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemse PH, van der Zee AG, Suurmeijer AJ (1999). Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer Res. 5: 2798–2805.
   PubMed Web of Science ®Google Scholar
• Bartel DP (2004). MiRNAs: genomics, biogenesis, mechan-ism, and function. Cell 116: 281–297.
   PubMed Web of Science ®Google Scholar
• Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sultmann H, Lyko F (2007). The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 67: 1419–1423.
   PubMed Web of Science ®Google Scholar
• Cannistra SA (2004). Cancer of the ovary. N. Engl. J. Med. 351: 2519–2529.
   PubMed Web of Science ®Google Scholar
• Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE (2008). Elevated expression of the miRNA-17–92 polycistron and miRNA-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am. J. Pathol. 173:856–64.
   PubMed Web of Science ®Google Scholar
• Dey N, Ghosh-Choudhury N, Kasinath BS, Choudhury GG (2012). TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One 7: e42316.
   Web of Science ®Google Scholar
• Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W, Grizzle WE, Alvarez RD, Stockard CR, LoBuglio AF, Buchsbaum DJ (2007). Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol. Oncol. 105: 291–298.
   PubMed Web of Science ®Google Scholar
• Frederick PJ, Kendrick JE, Straughn JM Jr, Della Manna DL, Oliver PG, Lin HY, Grizzle WE, Stockard CR, Alvarez RD, Zhou T, LoBuglio AF, Buchsbaum DJ (2009). Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. Int. J. Gynecol. Cancer 19: 814–819.
   PubMed Web of Science ®Google Scholar
• Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y (2012). MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol. Ther. 5: 330–340.
   Google Scholar
• Goff BA, Paley PJ, Greer BE, Gown AM (2001). Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol. Oncol. 81: 18–24.
   PubMed Web of Science ®Google Scholar
• Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E (2011). Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 286: 19127–19137.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alter H, Calin GA, Menard S, Croce CM (2007). MicroRNA signatures in human ovarian cancer. Cancer Res. 67: 8699–8707.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). Global cancer statistics. CA Cancer J. Clin. 61: 69–90.
   PubMed Web of Science ®Google Scholar
• Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW (2009). MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361: 1437–1447.
   PubMed Web of Science ®Google Scholar
• Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39: 673–677.
   PubMed Web of Science ®Google Scholar
• Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB (2009). MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 4: e7314.
   PubMed Web of Science ®Google Scholar
• Lengyel E (2010). Ovarian cancer development and metastasis. Am. J. Pathol. 177: 1053–1064.
   PubMed Web of Science ®Google Scholar
• Huang JS, Egger ME, Grizzle WE, McNally LR (2013). MicroRNA-100 regulate IGF1-receptor expression in metastatic pancreatic cancer cells. Biotech. & Histochem.. 88: 397–402.
   PubMed Web of Science ®Google Scholar
• Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S (2008). MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 14: 2690–2695.
   PubMed Web of Science ®Google Scholar
• Odar K, Boštjančič E, Gale N, Glavač D, Zidar N (2012). Differential expression of microRNAs miR-21, miR-31, miR-203, miR-125a-5p and miR-125b and proteins PTEN and p63 in verrucous carcinoma of the head and neck. Histopathology 61: 257–265.
   PubMed Web of Science ®Google Scholar
• Punnonen R, Teisala K, Kuoppala T, Bennett B, Punnonen J (1998). Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer 83: 788–796.
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425–336.
   PubMed Web of Science ®Google Scholar
• van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA (2010). MicroRNAs in ovarian cancer biology and therapy resistance. Int. J. Biochem. Cell Biol. 42: 1282–1290.
   PubMed Web of Science ®Google Scholar
• Waldman SA, Terzic A (2007). Translating MiRNA discovery into clinical biomarkers in cancer. JAMA 297: 1923–1925.
   PubMed Web of Science ®Google Scholar
• Wang YS, Wang YH, Xia HP, Zhou SW, Schmid-Bindert G, Zhou CC (2012). MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev. 13: 255–260.
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348–2360.
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC (2006). Unique miRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.
   PubMed Web of Science ®Google Scholar
• Yang L, Li N, Wang H, Jia X, Wang X, Luo J (2012). Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol. Rep. 28: 592–600.
   PubMed Web of Science ®Google Scholar
• Zhang, Y, Li, M, Wang, H, Fisher, WE, Lin, PH, Yao, Q, Chen, C (2009). Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real Time PCR Analysis. World J. Surg. 33: 698–709.
   PubMed Web of Science ®Google Scholar